

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



ImmuneOnco Biopharmaceuticals (Shanghai) Inc.

宜明昂科生物醫藥技術（上海）股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 1541)

(1) RESIGNATION OF SUPERVISOR; AND (2) ELECTION OF EMPLOYEE REPRESENTATIVE SUPERVISOR

The board (the “**Board**”) of directors (the “**Directors**”, each a “**Director**”) of ImmuneOnco Biopharmaceuticals (Shanghai) Inc. (the “**Company**”, together with its subsidiaries, the “**Group**”) announces the following changes to the supervisory committee (“**Supervisory Committee**”) of the Company:

RESIGNATION OF SUPERVISOR

Mr. Gu Jiefeng (顧傑鋒) (“**Mr. Gu**”) has tendered his resignation as a member of the Supervisory Committee of the Company, with effect from July 29, 2024, in order to devote more time to his other business commitments.

Mr. Gu has confirmed that he has no disagreement with the Supervisory Committee and there is no matter in relation to his resignation that needs to be brought to the attention of The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”) and the shareholders of the Company (the “**Shareholders**”).

The Supervisory Committee would like to express its sincere gratitude to Mr. Gu for his valuable contribution to the Company during his tenure of service.

ELECTION OF EMPLOYEE REPRESENTATIVE SUPERVISOR

Pursuant to the Company Law of the People's Republic of China and the articles of association of the Company, Ms. Zhang Wei (張薇) (“**Ms. Zhang**”) has been elected by the employee representative assembly as an employee representative supervisor, for a term of office commencing from July 29, 2024 until the date of expiry of the term of the first session of the Supervisory Committee.

The biographical details of Ms. Zhang are set out below:

Ms. Zhang, aged 36, joined the Group as a cell scientist in January 2013. She was promoted in February 2016 and has been serving as a director of upstream processing since then.

Ms. Zhang obtained a bachelor's degree in bioengineering and a master's degree in biochemical engineering from Shanghai University (上海大學) in the PRC in June 2010 and June 2013, respectively.

As of the date of this announcement, Ms. Zhang held approximately 4% partnership interests as a limited partner in Jiaxing Changxian Enterprise Management L.P. (Limited Partnership) (嘉興昶咸企業管理合夥企業(有限合夥)) (one of the employee shareholding platforms of the Company), representing an indirect interest of approximately 0.17% of the Company's total issued share capital.

As of the date of this announcement, save as disclosed above, Ms. Zhang had confirmed that: (i) she did not have any relationship with any other Directors, supervisors, senior management, substantial Shareholders, or controlling Shareholders of the Company (as respectively defined in the Listing Rules); (ii) she did not have any interest in the shares of the Company within the meaning of Part XV of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong); (iii) she did not hold any other positions within the Group; and (iv) she did not hold any directorships in any other public companies, the securities of which are listed on any securities market in Hong Kong or overseas in the last three years.

Save as disclosed above, to the best knowledge, information and belief of the Directors having made all reasonable enquiries, there is no other information relating to the election of Ms. Zhang that is required to be disclosed pursuant to the requirements of Rules 13.51(2)(h) to (v) of the Listing Rules and there are no other matters in relation to her appointment that need to be brought to the attention of the Shareholders.

The Company will enter into a service contract with Ms. Zhang for a term commencing from the date of the election of Ms. Zhang and ending on the expiry of the term of the first session of the Supervisory Committee, provided that her term of office will not exceed three years, and Ms. Zhang is eligible for re-election upon the expiry of her term of office in accordance with the articles of association of the Company. Her remuneration will be determined by the Shareholders' meeting with reference to Ms. Zhang's roles and responsibilities with the Company, prevailing market conditions and the remuneration policy of the Company, and will be disclosed in the annual report of the Company in due course.

By order of the Board
ImmuneOnco Biopharmaceuticals (Shanghai) Inc.
宜明昂科生物醫藥技術（上海）股份有限公司
Tian Wenzhi
Chairman and Executive Director

Hong Kong, July 30, 2024

As at the date of this announcement, the Board of Directors comprises (i) Dr. Tian Wenzhi, Mr. Li Song and Ms. Guan Mei as executive Directors; (ii) Dr. Xu Cong, Mr. Yu Zhihua and Mr. Yu Xiaoyong as non-executive Directors; and (iii) Dr. Zhenping Zhu, Dr. Kendall Arthur Smith and Mr. Yeung Chi Tat as independent non-executive Directors.